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Summary A humanised bispecific monoclonal antibody (bsMAb) with binding specificity for carcinoem-
bryonic antigen (CEA) on one arm and a radiolabelled chelate (DTPA-9Y) on the other arm was generated by
consecutively transfecting the humanised genes of an anti-CEA MAb and the chimerised genes of an
anti-chelate MAb into eucaryotic BHK cells using the calcium-phosphate coprecipitation technique. The
antibodies secreted were of IgG3 isotype with a shortened hinge region (A gamma 3) and light chains. Double
transfectomas were screened for the secretion of bsMAbs using a double determinant enzyme-linked immuno-
sorbent assay (ELISA) based on solid phase attached HSA-benzyl-DTPA and an anti-idiotypic MAb selective
for the CEA-specific arm. After purification on two immunoaffinity chromatography columns, the humanised
bsMAbs were characterised by SDS-PAGE and a quantitative binding assay in antigen excess. The purification
procedure resulted in 95% reactive bispecific MAb. This humanised bsMAb may be employed in two phase
radioimmunotherapy, binding to the tumour via the anti-CEA arm and localising a radiolabelled chelate with
the other arm, without inducing a strong immune response observed sometimes with murine MAbs.
Besides the important role of murine monoclonal antibodies
(MAbs) in basic research and in vitro diagnosis, they became
important tools for in vivo diagnosis of tumours (Murray &
Unger, 1988), inflammatory processes (Joseph et al., 1988)
and thrombosis (Haber et al., 1990). Furthermore it was
clinically proven that murine MAbs inhibit transplantation
rejection (Goldstein, 1987; Kurrle et al., 1988) and interfere
with gram negative sepsis (Greenman et al., 1991). No clear-
cut clinical benefit, however, was shown so far in the therapy
of solid tumours either with cytotoxic murine MAbs or
MAb-drug conjugates (Dykes et al., 1987). This is mainly
due to the unfavourable tumour tissue penetration charac-
teristics and whole body distribution of macromolecules such
as MAbs (Thomas et al., 1989), causing severe damages in
normal tissue as well. This can be optimised using the
recently described two phase immunotherapy approaches
(Bosslet et al., 1991) based on bispecific MAbs. BsMAbs
offer a unique possibility for the two phase immunotherapy
consisting of a long-term binding phase of the nontoxic
bsMAbs to tumour cells and, after the elimination of un-
bound bsMAb, a short-term binding phase of an effector
system. In our approach, we intend to use a bsMAb with
binding specificity for a tumour associated antigen (carcino-
embryonic antigen, CEA) on one arm and to a radiolabelled
chelate (DTPA-9Y) on the other arm for a two phase radio-
immunotherapy.
BsMAbs have been generated either by chemical linking of
the reduced monovalent parental Fab' fragments to form a
bispecific F(ab')2 fragment (Brennan et al., 1985; Bagshawe et
al., 1989), using the quadroma technique (Milstein & Cuello,
1983), by double transfection of murine Ig genes (Lenz &
Weidle, 1990) or by double transfection of chimeric DNA
constructs (Songsivilai et al., 1989). A murine bsMAb with
the above mentioned specificities, generated by double fusion
has already been described (Bosslet et al., 1991).
Unfortunately repetitive high dose injection of murine
monoclonal antibodies in immunotherapy often induced the
development of human anti-mouse-Ig antibodies (HAMA) in
patients, which prevent prolonged treatment (Miller et al.,
1983; Kroonenburgh, van & Pauwels, 1988). Consequently,
the target was to produce a MAb capable ofescaping surveil-
lance by the human immune system while retaining the speci-
ficity of the murine parental antibody. In a first approach,
the V-regions of murine antibodies were recombined with
human constant region genes to form chimeric MAbs (Bouli-
anne et al., 1984; Morrison et al., 1984). Lately, the antigen
binding loops or complementarity-determining regions
(CDRs) of the mouse VH and VL domains have successfully
been transplanted to the VH and VL domains of human
myeloma proteins without major impairment of the antigen
binding capacity (Jones et al., 1986; Riechmann et al., 1988).
One of these humanised MAb has already been applied in
patients (Hale et al., 1988), without inducing a detectable
immune response against the molecule.
In this report, we describe the generation of a bifunctional
MAb consisting of one humanised anti-CEA arm and a
chimerised anti-DTPA-Y arm by double transfection of the
corresponding genes into BHK cells, its purification using
immunoaffinity chromatography and its characterisation.
Materials and methods
Production ofCEA- andDTPA-specific murine MAbs
The generation and screening of murine MAbs directed
against CEA (BW 431) and DTPA-Y (BW 2050), respectively,
was described previously (Bosslet et al., 1988 and 1991).
Chimerisation ofan anti-DTPA-Y MAb
The murine variable (VH and VL) region genes of the heavy
and light chain of MAb BW 2050 were recombined with the
constant region genes of human IgGs (Ay3) according to the
method of Boulianne et al. (1984) (Figure 1).
Humanisation ofan anti-CEA MAb
The sequences of the heavy and light chain variable genes of
MAb BW 431 (anti-CEA) were amplified and cloned as des-
cribed by Orlandi et al. (1989) and the CDR regions were
subsequently built into the framework of human VH and VL
domains according to the methodology of Jones et al. (1986)
and Riechmann et al. (1988) (Figure 1). The exact procedure
for the humanisation of MAb BW 431 was described by
Gussow and Seemann (1991).
Expression ofhumanised bsMAb
First, the expression vectors carrying the heavy and light
chain genes of humanised MAb BW431 were transfected
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Figure 1 Schematic diagrams of the expression plasmids pAb,
used for double transfection, containing the murine (black) CDRs
of light a, and heavy b, chain of MAb BW 431 (anti-CEA) or the
variable region of light c, and heavy d, chain of MAb BW 2050
(anti-DTPA-Y) respectively, joined to the human (white) A
gamma 3 and kappa constant regions. SV40 promoter and CMV
enhancer are shown as well as the drug resistance marker ampi-
cillin (amp).
into eucaryotic BHK cells (ATCC CCL10, American Type
Culture Collection, Rockville, Md., USA) using the Calcium-
phosphate precipitation technique (Graham & van der Eb,
1973). Two plasmids carrying resistance genes for methotrex-
ate (Subramani et al., 1981) and G418 (Hudziak et al., 1982)
as selection markers were cotransfected. A BHK cell line
which had been selected for the production of humanised
anti-CEA MAb and the binding of anti-idiotypic antibody
(Gussow & Seemann, 1991) was transfected a second time
with the chimeric genes coding for the heavy and light chains
of MAb BW 2050. The resistance gene for hygromycin (Gritz
& Davies, 1983) was cotransfected for the selection of double
transfectomas.
Cells were seeded out in a modified Dulbecco's medium
containing human insulin and all three resistance markers
(Mtx, G418, hygromycin). Clones grew out 2-3 weeks after
transfection.
Screening ofthe double transfectomas
Transfectoma supernatants were screened for the presence of
bispecific MAb using an ELISA system in which HSA-
benzyl-DTPA (50 ng ml-') was attached to the solid phase of
round bottom polystyrol plates (Nunc). Bound MAb was
detected using a murine anti-idiotypic antibody (IgG2b)
(Bosslet et al., 1990), selective for the murine as well as the
humanised anti-CEA MAb BW 431, and an alkaline phos-
phatase labelled goat anti-mouse-IgG2b antibody (Southern,
Birmingham, USA) combined with the alcohol dehydrogen-
ase-diaphorase amplification system (Stanley et al., 1985;
system III). Optical density was measured at 493 nm using a
Titertek multiscan type 3100 (Flow Laboratories).
Double affinity chromatography
Protein A-sepharose-purified anti-idiotypic MAb specific for
BW 431 was coupled to cyanogen bromide-activated Sepha-
rose at a concentration of 6.5 mg MAb ml- gel according to
van Eijk and van Noort (1976). Supernatant of double trans-
fectoma was loaded on the column. After extensive washing
with phosphate-buffered saline (PBS), pH 7.2, specifically
bound antibodies were eluted using PBS, pH 4.0. On a
second column, antigen (HSA-benzyl-DTPA) was covalently
coupled to CNbr-activated Sepharose at a concentration of
8 mg ml-' gel. The MAb eluted from the anti-id column was
loaded on the HSA-benzyl-DTPA column. After washing
with PBS, pH7.2, the bispecific MAbs were eluted with
double distilled water containing 25% glycerine, and adjusted
to pH 2.3
The enrichment of bispecific MAb was monitored using
three ELISA systems which allowed the determination of the
functional anti DTPA arm (system 1), a functional anti CEA
arm (system 2) or both arms (system 3). Technical details of
the systems are identical to those described in screening of
the double transfectomas.
System I uses HSA benzyl-DTPA on the solid phase (coat-
ing concentration: 50 ngml-') combined with AP-labelled
anti human K antibody (50 ng ml-', Southern Biotechnology
h.c., Birmingham).
In system II CEA at a concentration of 50ngml-' was
attached to the solid phase instead of HSA-benzyl-DTPA.
System III was described in chapter 'Screening of the
double transfectomas'.
Characterisation ofbsMAbs in SDS-Polyacrylamide-gel
electrophoresis
Samples were analysed either unreduced or reduced with
50mM DTT by SDS-PAGE (Laemmli, 1970), carried out in
a Mini Protean II Electrophoresis Cell (Bio-Rad, Richmond,
Ca., USA) using a 10% stacking gel combined with a separa-
tion gel of 4-15% (Bio-Rad). The gels were stained using
Coomassie Blue according to the manufacturers' procedure
(PhastGel'm Blue R, Pharmacia LKB, Sweden).
Quantitative binding assay in antigen excess
Four hundred ng ml-' of purified humanised bispecific MAb
were incubated with increasing amounts of antigen. Antigen
consisted of CEA-expressing HT29 colon carcinoma xeno-
grafts which were fixed using 5% formaldehyde for 5 days
and squeezed after cutting in 1-3 mm3 cubes through a
stainless steel sieve. This methodology generates single dead
round cell bodies, defined as ACM (antigen containing
material). After a 4 h incubation at room temperature the
antigen was spun down and the amount of unbound MAb in
the supernatant was determined using a quantitative ELISA
specific for human IgG (anti-human-IgG attached to the
solid-phase). The fraction of unbound MAb detectable in the
supernatant in antigen excess represents the inactive fraction
of the purified bsMAb preparation. Immunoreactivity (I.R.)
was determined according to the formula
I.R. = 100% -
100% x IgG-concentration at point of determination
Input IgG-concentration
The point of determination was the highest amount of anti-
gen at which there was no unspecific binding of the chimeric
negative control MAb BW 554, selective for ganglioside GD2.
Evaluation ofthe anti DTPA-arm
One fg ml-' of HSA-Benzyl-DTPA-Y was used to coat
microtitre plates. Constant amounts (1I00 tgml-') of bsMAb
purified by affinity chromatography were mixed with increas-
ing amounts of DTPA-Y starting with 0.1ngml-' up to
1 ttgml-' in 1:4 fold dilution. After incubation of the mix-
ture in the coated wells for 30' at RT, bound bsMAb was
detected using an AP-labelled anti human K antibody as
combined with the ADH-diaphorase amplification system.
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Results
Generation ofhumanised anti-CEA x anti-DTPA-YbsMAbs
By double transfection of BHK cells we produced clones
secreting bispecific IgG3 with one humanised anti-CEA arm
and a chimerised anti-DTPA-Y arm. Arising clones were
screened using a double determinant ELISA based on solid
phase attached HSA-benzyl-DTPA and anti-idiotypic anti-
body, selective for the CEA-specific arm (see Material and
methods; system III). Out of 730 clones that were isolated
2-3 weeks after transfection, three clones remained stable
producers of bsMAbs after two rounds of cloning. The clone
with the highest production rate was A 10/32/255, further
named A 10 or humanised bsMAb. A 10 produced 4-8 pg
MAb ml-' and was cultured in roller bottles in a modified
Dulbecco's medium supplemented with human insulin and
the resistance markers (G418, Mtx, hygromycin).
Purification ofhumanised bsMAb
Ten litres supernatant of clone A 10 were concentrated and
purified using two consecutive affinity chromatography col-
umns, first an anti-id column and second an antigen column.
The effect of the individual purification steps was investigated
using three different ELISAs, detecting the anti-DTPA-Y
arm (system I), the anti CEA arm (system II), and both arms
(system III). BsMAb could be separated from the non bi-
specific molecules which appear by false recombinations of
heavy and light chains. The data, presented in Table I, show
a) the increase of activity in system II (specific for CEA) after
anti-idiotypic affinity chromatography, and b) the increase of
activity in system I (specific for DTPA-Y) after antigen
affinity chromatography in the eluates in question. Coinci-
dental there is a decrease of activity in the flow throughs of
both columns.
Out of 32 mg of IgG which could be detected via ELISA
in 10 1 of supernatant of A 10, 3.1 mg were left over after
double immunoaffinity purification. The yield of 10% was in
the range suggested according to the theoretical considera-
tions from Milstein and Cuello (1983).
Table I ELISA for the evalution ofdoubleimmunoaffinity chromato-
graphy
Experimental procedure I II III
Concentrate before chromatography 1.220 0.990 0.240
(1:20)
Flow through a-id-column 1.200 0.340 0.100
Eluate (1:10) 0.330 1.100 0.340
Flow through antigen-column 0.250 0.350 0.170
Eluate (1:10) 0.440 0.920 0.350
Optical densityat492 nmindetection system: (I) HSA-benzyl-DTPA
solid phase + anti-K-AP; (II) CEA solid phase + anti-K-AP; (III) HSA-
benzyl-DTPA solid phase + anti-id (IgG2b) + anti-IgG2b-AP.
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Figure 2 SDS-Polyacrylamide gel electrophoresis (10% stacking
gel) with unreduced (lanes 1-3) and reduced (lanes 4-6) samples
of protein marker (lanes 1 and 4); monospecific humanised MAb
BW 431 (lanes 2 and 5); bsMAb A 10 (lanes 3 and 6). Molecular
weights in kDa.
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Characterisation ofthe humanised bsMAbs
In order to characterise the immunoaffinity purified human-
ised bsMAb and to investigate whether the bispecific mole-
cule retains the characteristics of the humanised monospecific
anti-CEA MAb 431, both molecules were compared using
SDS-PAGE.
In SDS-PAGE (Figure 2) both immunoglobulins showed a
major band with an apparent molecular weight of approxi-
mately 150 kDa and a minor band of approximately 125
kDa. Under reducing conditions, the humanised anti CEA
MAb showed a 50 kDa heavy chain and a 25 kDa light
chain, whereas in the bsMAb preparation two light chains
with an approximate molecular weight of 25 and 26.5 kDa
were detected in addition to a 50 kDa heavy chain band.
Quantitative binding capacity ofhumanised bsMAbs in antigen
excess
The immunoreactivity of the immunopurified bsMAb A 10
was determined in comparison to the humanised monospecific
anti-CEA MAb BW431 and an irrelevant chimeric antibody
(BW 554) in an ELISA after incubation of constant amounts
of antibody with increasing amounts of particle attached
CEA as described in Materials and methods (Figure 3).
Immunoreactivity was calculated, based on the IgG con-
centrations determined by ELISA, according to the formula
given in Materials and methods. Calculations indicated that
95% of the preparation of bispecific MAb consisted of
immunoreactive material, compared to 96% as determined
for the monospecific humanised MAb BW 431 (see Table II).
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Figure 3 ELISA for the quantitative evaluation of unbound
bispecific humanised MAb after double affinity chromatography.
Individual wells contained the antigen containing material
(ACM = CEA) (indicated on the abscissa) mixed with 400 ng of
humanised bsMAb A 10 ( ), with 400 ng of humanised
MAb BW 431 (. ), or with 400 ng of irrelevant chimeric MAb
BW 554 (------). Optical density expressed in mE (492 nm) at the
ordinate represents the amount of unbound MAb in the super-
natant of each antigen concentration. The arrow indicates the
point of determination.
Table II Immunoreactivity (I.R.), expressed as percentage, ofhuman-
ised bsMAb A 10 and humanised MAb BW 431
IgG-concentration IgG-concentration
(input) (p. ofdetermination) % IR.
hum. BW 431 400 ngml-' 15 ngml-' 96
hum. bispecific 468 ng ml-' 22 ngml-' 95
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Evaluation ofthe anti DTPA-Y arm
The binding potential of the bsMAb to HSA-benzyl DTPA-
Y was determined in a competitive ELISA system as des-
cribed in Materials and methods. Increasing amounts of
DTPA-Y as a competitor resulted in a decrease of the bind-
ing signal in the ELISA down to background level (data not
shown). These data indicate that free DTPA-Y is able to
block the binding of the bsMAb to solid phase attached
HSA-benzyl DTPA-Y, arguing for the functional integrity of
the anti DTPA-Y arm.
Discussion
We have established a humanised bispecific monoclonal anti-
body consisting of a humanised anti-CEA arm and a chime-
rised anti-DTPA-Y arm. The bispecific molecule is of IgG3
isotype and has a shortened hinge region: instead ofnormally
four, the AIgG3 gene has only one exon, reducing the possi-
ble disulfide bonds from 11 to 3. We were able to generate
this bsMAb by two successive, calcium-phosphate mediated
transfections of an eucaryotic BHK cell line. Out of several
hundred clones, only three stably produced bsMAbs detect-
able in a double determinant ELISA. For purification pur-
poses we had to load the culture supernatant on two
consecutive immunoaffinity chromatography columns, first
presenting an anti-idiotypic antibody, selective for the CEA
arm, and second the antigen for the anti-DTPA arm. Puri-
fication was controlled by three ELISA systems (Table I),
which proved that there was an increase of activity in the
eluates and a coincidental decrease of activity in the flow
through of the two columns. We were able to quantitatively
separate 10% of bispecific monovalent antibodies from false-
ly recombined molecules, a yield which correlates with the
theoretical considerations of Milstein and Cuello (1983).
Ninety-five per cent of the bispecific molecules were immuno-
reactive as revealed by a quantitative binding assay in anti-
gen excess (Table II). Compared to other methods (Doussal
et al., 1989; Lenz & Weidle, 1990) this purification method
leads to exceptionally high yields. Disadvantageous was the
yield of the BHK cells secreting the immunoglobulins: from a
cell line which had produced 4-8 g ml-' in the beginning,
we only harvested about 30 mg immunoglobulin from 101
supernatant instead of 40-80 mg expected. It has to be
accepted that to some extent the cells lost the specificity of
antibody production. In another case of antibody production
in BHK cells in our laboratory it was revealed that the cells
produced much more light chains than heavy chains (Bosslet,
unpublished data), a fact which leads to reduced yields of
intact molecules. Combined with the fact that two affinity
chromatography columns are necessary for purification, these
conditions are unfavourable for larger production scales.
Comparison of the humanised bsMAb and the humanised
monospecific anti-CEA antibody in SDS-PAGE proved that
both molecules resemble each other to a large extent. The
most obvious differences appear in the behaviour of the light
chains of both antibodies which point to the presence of two
different K-chains in the bsMAb (Figure 2, lanes 5 and 6).
This may be due to the fact that one of the light chains still
has a whole murine variable region. The integrity of the
bispecific MAb was further proven by our immunoreactivity
studies indicating that >95% of the bispecific humanised
MAb were functionally active. This immunoreactivity is only
marginally inferior to the value generated using the human-
ised monospecific MAb (>96%-.
The anti DTPA-Y could only be evaluated qualitatively.
Data from the competitive ELISA system in which the bind-
ing of the bsMAb to solid phase attached HSA-benzyl
DTPA-Y was completely blocked by a > 100 fold excess of
free DTPA-Y, argue for the functional integrity and speci-
ficity of those bsMAb molecules which bound to the solid
phase attached HSA-benzyl DTPA-Y. This type ofanalysis is
less quantitative than the immunoreactivity assay performed
for the anti CEA arm, but is nevertheless suited to support
the usefulness of the hu bsMAb.
The bispecific MAb generated is intended to be employed
in two phase radioimmunotherapy, having dual specificity for
carcino-embryonic antigen (CEA) and a radiolabelled chelate
(DTPA-90Y). Concerning the specific tumour localisation,
Bosslet et al. (1991) showed that it is possible to obtain a
significant tissue penetration of solid human carcinoma xeno-
grafts after long time application of the murine anti-CEA
MAb BW 431. Since the two phase therapy concept is built
up on repetitive long-term and high dose injections of
bispecific antibodies, immunisation of patients is most prob-
able. The humanised bsMAb is hoped to overcome the prob-
lem of immunogenicity currently seen with murine and
chimeric antibodies used in human therapy (Briiggemann et
al., 1989).
Considering the yields and the cumbersome purification
procedure, attempts have been made to improve the yield of
bispecific monovalent MAb using recombinant DNA techno-
logy, e.g. the construction of an Ig heavy chain, consisting of
VH of MAB 1 and a CHl domain, which is linked by a
polypeptide spacer to the other heavy chain, consisting of VH
of MAb 2 and a CH3 domain, to form a 'tandem heavy
chain'. The association of such a 'tandem heavy chain' with
the two corresponding light chains (VK of MAb 1 and a Cx
domain or VK of MAb 2 and a CH3 domain) should lead
predominantly to the formation of the desired bispecific
molecule.
The technical assistance of N. Doring, E. Herz, H. Lind and M.
Matthai as well as the secretarial assistance of S. Lehnert are greatly
appreciated.
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